Drug-target identification in Drosophila cells: combining high-throughout RNAi and small-molecule screens.
RNA interference (RNAi) and small-molecule approaches are synergistic on multiple levels, from technology and high-throughput screen development to target identification and functional studies. Here, we describe the RNAi screening platform that we have established and made available to the community through the Drosophila RNAi Screening Center at Harvard Medical School. We then illustrate how the combination of RNAi and small-molecule HTS can lead to effective identification of targets in drug discovery.
Perrimon
Norbert
N
Department of Genetics, Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115, USA. perrimon@receptor.med.harvard.edu
Friedman
Adam
A
Mathey-Prevot
Bernard
B
Eggert
Ulrike S
US
D000818:Animals; D004330:Drosophila / Q000166:cytology / Q000235:genetics; D016503:Drug Delivery Systems / Q000379:methods*; D015195:Drug Design; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000235:genetics
D034741:RNA, Small Interfering